期刊文献+

吉西他滨对人鼻咽癌细胞系CNE-1的放射增敏作用 被引量:1

Radiosensitive effect of gemcitabine on nasopharyngeal carcinoma CNE-1 cell line
下载PDF
导出
摘要 目的:观察吉西他滨对鼻咽癌细胞CNE-1的放射增敏作用并探讨其作用机理。方法:用克隆形成法制作不同处理条件的细胞存活曲线,用流式细胞仪分析测定细胞周期分布。结果:单纯用药0.1μmol/L和2μmol/L吉西他滨短时间作用时(12小时)未见到肿瘤细胞毒性作用。两个浓度的吉西他滨处理CNE-1鼻咽癌细胞12小时和24小时后均见到放射增敏作用,放射增敏比(SERD0)及2Gy时的放射增敏比(SERSF2)分别为1.36,1.83;1.56,2.16及1.55,1.36,1.43,1.40。0.1μmol/L和2μmol/L的吉西他滨作用24小时后照射均见到G1期细胞阻滞。准阈剂量(Dq)值在2μmol/L中比较低,特别是在作用24小时后照射组。结论:吉西他滨对CNE-1鼻咽癌细胞具有明显的放射增敏作用,并且在高剂量照射时(Gy)随着剂量的增加及作用时间的延长增敏作用愈加明显,其作用机制可能与该药能阻止细胞由G1期进入S期及在高浓度、长时间作用时亚致死性损伤修复比较少有关。 Objective:To observe the effect and mechanism of gemcitabine-induced radiosensitization on CNE-1 nasopharyngeal carcinoma cell line.Methods:The cell survival curves were obtained by clonogenic assay.The cell cycle phases were measured with flow cytometric analysis.Results:No cytotoxic effect was observed in the groups treated with 0.1μmol/L and 2μmol/L gemcitabine lonely.The radiosensitivities were observed in groups treated with both radiation and gemcitabine(0.1μmol/L and 2μmol/L) after exposed 12hours and 24hours,respectively.The SERD0 were 1.36,1.83 and 1.56,2.16 respectively.The G1 cell cycle phase block was observed in two consistency groups after exposing for 24 hours.Dq were rather lower in 2μmol/L groups especially that exposed for 24 hours.Conclusion:The radiosensitivity was obviously observed in radiation groups treated with both 0.1μmol/L(lower dose)and 2μmol/L(higher dose) gemcitabine.The effect was more obviously as the consistency and the exposing time increased.The block of cell cycle from G1 to S and decrease of sublethal damage repair might be contributed to the mechanism.
出处 《现代肿瘤医学》 CAS 2010年第9期1711-1713,共3页 Journal of Modern Oncology
基金 沈阳市社会事业科技创新项目(编号:1081269-9-00)
关键词 吉西他滨 放射增敏 鼻咽癌细胞CNE-1 gemcitabine radiosensitivity CNE-1
  • 相关文献

参考文献9

  • 1Galloway NR,Aspe JR,Sellers C,et al.Enhanced antitumor effect of combined gemcitabine and proton radiation in the treatment of pancreatic cancer[J].Pancreas,2009,38(7):782-90.
  • 2Aguilar-ponce J,Granados-Garcia M,Villavicencio V,et al.Phase Ⅱ trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck[J].Ann Oncol,2004,15:301-306.
  • 3Eisbruch S,Shewach DS,Bradford CR,et al.Radiation concurrent with gemcitabine for locally advanced head and neck cancer:a phase Ⅰ trial and intracellular drug incorporation study[J].J Clin Oncol,2001,19:792-799.
  • 4Choy H.Combination chemoradiotherapy with gemcitabine:potential applications[J].Oncology (Huntingt),2000,14 (7Suppl 4):20-25.
  • 5马熙天,李庆萍,邱金宝.低剂量健择增敏放疗治疗胰腺癌的临床分析[J].江西医药,2008,43(2):98-100. 被引量:1
  • 6Mose S,Karapetian M,J uling2Pohlit L,et al.Rediation enhancement of gemcitabine in two human squamous cell carcinoma cell lines[J].Anticancer Res,2000,20(1A):401-405.
  • 7李坚,王仁生,甘浪舸.健择对人鼻咽癌细胞系放射增敏机制的实验研究[J].中国肿瘤临床,2006,33(13):734-737. 被引量:6
  • 8高春玲,高春丽,宋维芳,谢立青.放射增敏剂的增敏机制[J].现代肿瘤医学,2007,15(6):890-892. 被引量:5
  • 9Chang JT,Ko JY,Hang RL.Recent advances in the treatment of nasopharyngeal carcinoma[J].J Formos Med Assoc,2004,103:496-510.

二级参考文献38

  • 1周桂霞,崔书祥,马林,徐寿平.三维适形放射治疗胰腺癌临床探讨[J].中华肝胆外科杂志,2005,11(10):668-670. 被引量:8
  • 2房彤,刘丽,高宏,孙保锦,陈力.不同剂量分割模式的三维适形放疗对局部进展期胰腺癌的疗效分析[J].中国肿瘤临床与康复,2007,14(3):224-226. 被引量:4
  • 3吴慧,邱荣良,李定杰,王建华,张景伟,陈奎生.三维适形放射治疗晚期胰腺癌近期疗效分析[J].中国肿瘤临床与康复,2007,14(4):324-325. 被引量:1
  • 4Ostruszka LJ,Shewach DS.The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine[J].Cancer Res,2000,60(21):6080~6088
  • 5Halm U,Schumann T,Schiefke I,et al.Decrease of CA 19-9during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer[J].Br J Cancer,2000,2(5):1013~1016
  • 6Dalbagni G,Russo P,Sheinfeld J.Phase Ⅰ trial of intravesical gemcitabine in bacillus-calmette-Guerin-refractory transitional cell carcinoma of the bladder[J].J Clin Oncol,2002,20(15):3193~3198
  • 7Hertel LW,Boder GB,Kroin JS,et al.Evaluation of the antitumor activity of gemcitabine[J].Cancer Res,1990,50 (14):4417 ~4422
  • 8Burris HA,Moore MJ,Andersen J,et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol,1997,15(6):2403~2413
  • 9Shewach DS,Hahn TM,Chang E,et al.Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells[J].Cancer Res,1994,54(12):3218~3223
  • 10Kotchetkov R,Groschel B,Gmeiner WH,et al.Antineoplastic activity of a novel multimeric gemcitabine-monophosphate prodrug against thyroid cancer cells in vitrol[J].Anticancer Res,2000,20(5A):2915~2922

共引文献9

同被引文献6

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部